Latest News

2024 Genprex Letter to Stockholders

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Genprex to Present at the 2024 BIO International Convention

Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors

Genprex to Present and Participate at Upcoming May Investor and Industry Conferences

About Us

Why Genprex?

At Genprex, we are dedicated to transforming the lives of patients battling cancer and diabetes through pioneering gene therapies. Utilizing our proprietary non-viral gene therapy platform, we deliver novel treatments aimed at addressing unmet medical needs. Our innovative approach focuses on reintroducing tumor suppressor genes to combat cancer and using gene therapy to stabilize glucose levels in diabetes. With multiple FDA Fast Track Designations and promising clinical trial results, Genprex is at the forefront of medical advancements, striving to bring hope and improved outcomes to patients worldwide.

Download Our Deck

Reasons to Invest:

Innovative Gene Therapy Platform: Genprex’s proprietary non-viral delivery system offers a unique approach to treating cancer and diabetes, setting us apart in the biotechnology landscape.
Clinical Success and FDA Designations: With three FDA Fast Track Designations and one Orphan Drug Designation, our therapies have shown promise in clinical trials, enhancing our potential for regulatory approval and market success.
Expansive Market Potential: Addressing major health challenges such as lung cancer and diabetes, our therapies have the potential to tap into multi-billion dollar global markets.

Our Growth Plan

Genprex, Inc. is poised for growth in gene therapy, focusing on cancer and diabetes treatment. With our ONCOPREX® Delivery System, we're advancing novel therapies, including REQORSA® for lung cancer, where we have promising Phase 1 and 2 results that underscore our potential here. Collaborations with top institutions strengthen our R&D.

We are currently enrolling three clinical trials of REQORSA in lung cancer: Acclaim-1, Acclaim-2 and Acclaim-3. All three of our Acclaim clinical trials have received U.S. Food and Drug Administration (FDA) Fast Track Designation, and Acclaim-3 also has FDA Orphan Drug Designation for the treatment of SCLC. Our innovative diabetes gene therapy program utilizes an adeno-associated virus (AAV) vector containing the Pdx1 and MafA genes, which are administered directly into the pancreatic duct to transform alpha cells in the pancreas into functional beta-like cells that can produce insulin or to rejuvenate and replenish exhausted beta cells.

Looking forward, Genprex aims to lead in gene therapy innovation, expanding into new indications and modalities to meet diverse medical needs. Our commitment to maximizing shareholder value through prudent financial management and strategic alliances underscores our dedication to transforming patient care globally. With a seasoned team and a clear vision, Genprex is poised to redefine treatment standards and improve patient outcomes worldwide.